Results 31 to 40 of about 1,334 (146)

Pigment Epithelium‐Derived Factor (PEDF)‐Based Therapy Induced Photoreceptor Survival by Stabilizing Choroidal Neovessels in a VEGF Overexpression CNV Rat Model

The FASEB Journal, Volume 39, Issue 19, 15 October 2025.
Stabilizing choroidal neovessels offers a novel treatment‐option for pathological CNV. Pigment epithelium‐derived factor (PEDF), a multifunctional protein with vessel‐stabilizing properties, is a promising candidate for this approach. Its efficacy with and without bevacizumab was tested in a VEGF overexpression CNV rat model.
Alexander V. Tschulakow, Lei Xi, Ulrich Schraermeyer, Sylvie Julien   +3 more
wiley   +1 more source

Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison

Drug Target Insights
Objectives: To assess through an indirect treatment comparison (ITC) the potential benefit of faricimab over the anti-vascular endothelial growth factor (VEGF) real-life scenario, hereby defined standard of care (SoC), in Italy, that is, aflibercept ...
Carlotta Galeone, Federica Turati, Massimo Nicolò, Mariacristina Parravano, Stela Vujosevic, Laura Bianchino, Emilia Sicari, Paolo Lanzetta   +7 more
doaj   +1 more source

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

Advanced Science, Volume 12, Issue 39, October 20, 2025.
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz, Jessica Cutrufello, Michael Lam, Shreya Nallaparaju, Nicholas A. Peppas   +4 more
wiley   +1 more source

Conbercept Treatment for Heart‐Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti‐VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA

Clinical Case Reports, Volume 13, Issue 10, October 2025.
A 63‐year‐old male with a history of hypertension and diabetes developed acute vision loss, which was attributed to macular neovascularization secondary to hypertensive retinopathy. Optical coherence tomography angiography revealed unusual heart‐shaped, intertwined vascular nets, informing the choice of Conbercept for intravitreal injection.
Shangkun Ou, Feiping Shi, Minqing Cai, Yiming Wu   +3 more
wiley   +1 more source

Cytokine Engineering Approaches for Regenerative Medicine

Advanced Therapeutics, Volume 8, Issue 9, September 2025.
Engineered cytokines represent a powerful strategy to promote tissue repair and regeneration by precisely modulating immune responses. This review highlights recent advances in cytokine engineering, including strategies to enhance half‐life, improve tissue and cell targeting, and control receptor signaling.
Shiyi Li, Wenhao You, Mikaël M. Martino
wiley   +1 more source

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME

International Journal of Retina and Vitreous
Management of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong anti-VEGF injections with drugs like aflibercept, brolucizumab, ranibizumab ...
Fernando M Penha, Maliha Masud, Zoha A. Khanani, Mathew Thomas, Rodney D. Fong, Kyler Smith, Avishay Chand, Majid Khan, Greggory Gahn, Gustavo Barreto Melo, Arshad M. Khanani   +10 more
doaj   +1 more source

Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration

Life
Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict ...
Benjamin Ng, Hema Kolli, Naduviledeth Ajith Kumar, Matthew Azzopardi, Abison Logeswaran, Julius Buensalido, Bushra Mushtaq, Randhir Chavan, Yu Jeat Chong   +8 more
doaj   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, Volume 53, Issue 5, Page 523-528, July 2025.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source